Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Altimmune Regains Some Momentum

Executive Summary

Obesity drug pemvidutide looks better at nearly a year than it did at six months, but still lags rivals Wegovy and Zepbound.

You may also be interested in...



Stock Watch: GLP-1 Expectations Dashed

If oral GLP-1 agonists are going to be successful in a wider weight loss indication, lower efficacy may be the trade-off for better tolerability in this bigger and more healthy population.

The Future Of Obesity

Novo Nordisk and Eli Lilly are duking it out in the market, but dozens of competitors are waiting in the wings.

Altimmune’s Pemvidutide Garners Mixed Reviews Following Phase II Obesity Data

The US firm’s GLP-1/glucagon receptor agonist improved weight loss in a Phase II interim analysis, but concerns about drug safety and discontinuation have left investors cynical, even as analysts remain cautiously upbeat.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

SC149439

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel